A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

In all, their investment portfolio pulled in an estimated 54% return in 2024, more than double the S&P 500’s 25% gain — and ...

The UK's FTSE 100 saw its five-week winning streak halted, influenced by global tensions between Israel and Iran, and ...

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

The lawsuit stems from last month's report that claimed Tempus overstates its AI capabilities and engages in "aggressive ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...